Can a bispecific antibody wipe out stubborn CLL cells?
NCT ID NCT07052695
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This pilot study tests whether the drug mosunetuzumab, given alone or with a BTK inhibitor, can clear minimal residual disease (tiny amounts of leftover cancer) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 40 participants who have already been treated with a BTK inhibitor or BCL2 inhibitor will receive the drug combination. The goal is to see if this approach can achieve undetectable MRD in the bone marrow, which may lead to longer remissions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mosunetuzumab (a bispecific antibody) given alone or with a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib)
- What this could lead to
- If successful, this approach could help people with CLL or SLL achieve deeper remission by clearing leftover cancer cells that standard treatments miss.
- What could go wrong
- This is an early pilot study with only 40 participants, so results may not apply to everyone. Side effects from the immune-activating drug or combination therapy are possible, and the treatment may not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham & Women's Hospital
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?